PRME insider transaction filings
Prime Medicine, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-08. Screen PRME transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-08 | 4 | Chung Wendy — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Cahill Thomas — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Kelly Michael Aaron — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Marrazzo Jeffrey D — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Schenkein David P — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Foster-Cheek Kaye I — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | NELSEN ROBERT — Director, 10% owner | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Makhni Svetlana Ni — Chief Financial Officer | Grant/award (A): 800,000 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Reine Allan — Chief Executive Officer, Director | Grant/award (A): 1,300,000 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | LEE ANN L. — Chief Technical Officer | Grant/award (A): 375,000 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Alenson Carman — See Remarks | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Chung Wendy — Director | Disposition to issuer (D): 13,510 (derivative) · Grant/award (A): 13,510 (derivative) · Disposition to issuer (D): 9,006 (derivative) · Grant/award (A): 9,006 (derivative) · Disposition to issuer (D): 39,062 (derivative) · Grant/award (A): 39,062 (derivative) · +2 more | EDGAR |
| 2025-08-05 | 4 | Cahill Thomas — Director | Disposition to issuer (D): 39,062 (derivative) · Grant/award (A): 39,062 (derivative) · Disposition to issuer (D): 45,000 (derivative) · Grant/award (A): 45,000 (derivative) | EDGAR |
| 2025-08-05 | 4 | Kelly Michael Aaron — Director | Disposition to issuer (D): 13,510 (derivative) · Grant/award (A): 13,510 (derivative) · Disposition to issuer (D): 9,006 (derivative) · Grant/award (A): 9,006 (derivative) · Disposition to issuer (D): 39,062 (derivative) · Grant/award (A): 39,062 (derivative) · +2 more | EDGAR |
| 2025-08-05 | 4 | LEE ANN L. — Chief Technical Officer | Disposition to issuer (D): 180,995 (derivative) · Grant/award (A): 180,995 (derivative) · Disposition to issuer (D): 180,995 (derivative) · Grant/award (A): 180,995 (derivative) | EDGAR |
| 2025-08-05 | 4 | Reine Allan — Chief Executive Officer, Director | Disposition to issuer (D): 850,000 (derivative) · Grant/award (A): 850,000 (derivative) | EDGAR |
| 2025-08-05 | 4 | Alenson Carman — See Remarks | Disposition to issuer (D): 16,083 (derivative) · Grant/award (A): 16,083 (derivative) · Disposition to issuer (D): 90,498 (derivative) · Grant/award (A): 90,498 (derivative) · Disposition to issuer (D): 6,254 (derivative) · Grant/award (A): 6,254 (derivative) · +2 more | EDGAR |
| 2025-08-05 | 4 | GV 2021 GP, L.L.C. — 10% owner GV 2021 GP, L.P. — 10% owner GV 2021, L.P. — 10% owner Alphabet Inc. — 10% owner | Purchase (P): 1,500,000 @ $3.30 | EDGAR |
| 2025-08-05 | 4 | Marrazzo Jeffrey D — Director | Disposition to issuer (D): 92,000 (derivative) · Grant/award (A): 92,000 (derivative) · Disposition to issuer (D): 250,000 (derivative) · Grant/award (A): 250,000 (derivative) · Disposition to issuer (D): 45,000 (derivative) · Grant/award (A): 45,000 (derivative) | EDGAR |
| 2025-08-05 | 4 | Schenkein David P — Director | Disposition to issuer (D): 39,062 (derivative) · Grant/award (A): 39,062 (derivative) · Disposition to issuer (D): 45,000 (derivative) · Grant/award (A): 45,000 (derivative) | EDGAR |
| 2025-08-05 | 4 | Foster-Cheek Kaye I — Director | Disposition to issuer (D): 13,510 (derivative) · Grant/award (A): 13,510 (derivative) · Disposition to issuer (D): 9,006 (derivative) · Grant/award (A): 9,006 (derivative) · Disposition to issuer (D): 39,062 (derivative) · Grant/award (A): 39,062 (derivative) · +2 more | EDGAR |
| 2025-08-05 | 4 | NELSEN ROBERT — Director, 10% owner | Disposition to issuer (D): 39,062 (derivative) · Grant/award (A): 39,062 (derivative) · Disposition to issuer (D): 45,000 (derivative) · Grant/award (A): 45,000 (derivative) | EDGAR |
| 2025-08-01 | 4 | ARCH Venture Partners XII, LLC — 10% owner ARCH Venture Partners XII, L.P. — 10% owner ARCH Venture Fund XII, L.P. — 10% owner | Purchase (P): 3,030,300 @ $3.30 | EDGAR |
| 2025-08-01 | 4 | NELSEN ROBERT — Director, 10% owner | Purchase (P): 3,030,300 @ $3.30 | EDGAR |
| 2025-08-01 | 4 | ARCH Venture Partners X, LLC — 10% owner ARCH Venture Partners X, L.P. — 10% owner ARCH Venture Partners X Overage, L.P. — 10% owner ARCH Venture Fund X, L.P. — 10% owner ARCH Venture Fund X Overage, L.P. — 10% owner CRANDELL KEITH — 10% owner Burow Kristina — 10% owner GILLIS STEVEN — 10% owner | Purchase (P): 3,030,300 @ $3.30 | EDGAR |
| 2025-07-01 | 4 | Liu David R. — 10% owner | Purchase (P): 21,000 @ $2.52 | EDGAR |
| 2025-06-23 | 4 | Liu David R. — 10% owner | Purchase (P): 21,000 @ $2.16 | EDGAR |
| 2025-06-16 | 4 | Liu David R. — 10% owner | Purchase (P): 21,000 @ $1.49 | EDGAR |
| 2025-06-12 | 4 | Liu David R. — 10% owner | Purchase (P): 21,000 @ $1.60 | EDGAR |
| 2025-06-05 | 4 | Chung Wendy — Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Cahill Thomas — Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Kelly Michael Aaron — Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Marrazzo Jeffrey D — Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Schenkein David P — Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Foster-Cheek Kaye I — Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | NELSEN ROBERT — Director, 10% owner | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | LEE ANN L. — Chief Technical Officer | Purchase (P): 100,000 @ $1.13 | EDGAR |
| 2025-05-22 | 4 | Reine Allan — Chief Executive Officer, Director | Purchase (P): 125,000 @ $1.18 | EDGAR |
| 2025-05-22 | 4 | Brudnick Richard — Chief Business Officer | Purchase (P): 20,000 @ $1.19 | EDGAR |
| 2025-05-19 | 4 | Reine Allan — Chief Executive Officer, Director | Grant/award (A): 2,000,000 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Marrazzo Jeffrey D — Director | Grant/award (A): 800,000 (derivative) @ $0 | EDGAR |
| 2025-05-12 | 4 | LEE ANN L. — Chief Technical Officer | Grant/award (A): 80,416 (derivative) @ $0 | EDGAR |
| 2025-05-12 | 4 | Reine Allan — Chief Financial Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-05-12 | 4 | Gottesdiener Keith Michael — See Remarks, Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Gottesdiener Keith Michael — See Remarks, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Goldwasser Meredith — SVP, Strategy & Corporate Ops. | Grant/award (A): 90,500 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Duffield Jeremy — Chief Scientific Officer | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | LEE ANN L. — Chief Technical Officer | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Reine Allan — Chief Financial Officer | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Brudnick Richard — Chief Business Officer | Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Prime Medicine, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-08 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-08 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-03 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-08 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PRME returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →